10-Q: BioVie Reports Q1 Loss, AD Trial Integrity Concerns

BioVie Inc. reported an increased net loss for Q1 2026, raised $10.5 million in a public offering, and disclosed significant protocol violations in its Alzheimer's Phase 3 trial.

Summary

• Net loss for the three months ended September 30, 2025, increased to $5.09 million, compared to $4.15 million for the same period in 2024.
• Total operating expenses rose to $5.28 million from $4.12 million year-over-year, driven by increased research and development (R&D) and general and administrative (G&A) expenses.
• R&D expenses increased by $946,000 to $2.94 million, primarily due to the development and launch of the Long COVID program and Sunrise PD Phase 2 studies.
• G&A expenses increased by $216,000 to $2.29 million, mainly due to higher legal fees, investor relations, and filing fees, partially offset by reduced stock-based compensation.
• The company closed an underwritten public offering on August 11, 2025, generating approximately $10.5 million in net proceeds.
• Cash and cash equivalents increased to $24.98 million as of September 30, 2025, from $17.54 million at June 30, 2025.
• Working capital stood at approximately $24.4 million as of September 30, 2025.
• The company received a $13.1 million clinical trial grant from the U.S. Department of Defense (DOD) for its Long COVID program in April 2024, with $5.9 million incurred and reimbursed by November 10, 2025.
• Significant deviation from protocol and current good clinical practices (cGCPs) violations were found at 15 study sites in the Phase 3 Alzheimer's Disease (AD) trial, leading to patient exclusions and the trial being underpowered for primary endpoints.
• A preliminary signal of efficacy was observed in the Per-Protocol population of the AD trial, suggesting a slowing of cognitive loss and an advantage in age deceleration.
• The company faces ongoing securities class action and three shareholder derivative lawsuits alleging material misrepresentations and breach of fiduciary duties related to the AD trial.

Sentiment

Score: 3

Explanation: While the company secured significant financing and advanced some clinical programs, the increased net loss, the 'going concern' warning, and especially the severe protocol violations in the Alzheimer's Phase 3 trial (leading to underpowering and FDA OSI referral) are major negative factors. The ongoing legal proceedings also add significant uncertainty, outweighing the positive liquidity injection.

Positives

• Successfully raised approximately $10.5 million in net proceeds from an underwritten public offering in August 2025, significantly bolstering cash reserves.
• Cash and cash equivalents increased to $24.98 million as of September 30, 2025, from $17.54 million at June 30, 2025, improving liquidity.
• Awarded a $13.1 million clinical trial grant from the U.S. Department of Defense for the Long COVID program, with $5.9 million already reimbursed.
• Received FDA permission to proceed with a new Phase 2b study of bezisterim for new-onset Parkinson's Disease, which commenced in April 2025.
• FDA authorized the Investigational New Drug (IND) application for bezisterim to study neurological symptoms associated with Long COVID, with the trial commencing in May 2025.
• Previous Phase 2 study of bezisterim for Parkinson's Disease met primary objectives for safety and drug-drug interaction, and secondary objectives for promotoric activity and levodopa enhancement.
• BIV201 (continuous infusion terlipressin) for advanced liver disease has been granted both FDA Fast Track designation and FDA Orphan Drug Status.
• Interest expense decreased by approximately $254,000 due to the payoff of notes payable on December 1, 2024.

Negatives

• Net loss increased to $5.09 million for the three months ended September 30, 2025, compared to $4.15 million for the same period in 2024.
• The accumulated deficit grew to approximately $357.3 million as of September 30, 2025.
• Significant protocol deviations and cGCP violations were identified at 15 study sites in the Phase 3 Alzheimer's Disease trial, leading to the exclusion of patients and the trial being underpowered for its primary endpoints.
• The company referred the problematic AD study sites to the FDA Office of Scientific Investigations (OSI) for potential further action, indicating serious data integrity issues.
• Management has expressed 'substantial doubt on the Company's ability to continue as a going concern' due to its pre-revenue stage and dependence on securing additional financing.
• Ongoing securities class action and three shareholder derivative lawsuits allege material misrepresentations and breach of fiduciary duties, creating legal and financial uncertainty.
• Ratchet adjustments to warrants from previous capital raises resulted in deemed dividends of $43,544 and $325,041 for the three months ended September 30, 2025 and 2024, respectively, indicating dilution for existing warrant holders.

Risks

• Reliance on third parties (CROs, clinical trial sites, manufacturers) to conduct clinical trials, with risks of non-compliance with cGCPs and regulatory requirements, potentially delaying or invalidating trial results.
• Future equity offerings or issuance of shares subject to options, warrants, or other arrangements could lead to significant dilution for existing stockholders.
• The exercise price for outstanding warrants held by Acuitas Group Holdings, LLC could adjust downward if future equity sales occur at a lower deemed issuance price.
• Obligation to issue up to 180,000 shares of common stock upon achievement of certain clinical, regulatory, and commercial milestones for acquired drug candidates, further diluting existing shareholders.
• Inability to raise additional capital on acceptable terms to finance operations, which raises substantial doubt about the company's ability to continue as a going concern.
• Uncertainty regarding the outcome of the consolidated securities class action and shareholder derivative lawsuits, which could result in significant monetary damages and legal expenses.
• Concentration of credit risk due to cash deposits in financial institutions exceeding federally insured levels.

Future Outlook

The company is finalizing the protocol design for a Phase 3 study of BIV201, targeting a broader ascites patient population, specifically those who have recently recovered from acute kidney injury. For the Alzheimer's Disease program, the company is considering either employing an adaptive trial feature to continue enrolling patients to achieve statistical significance or designing a new Phase 3 study for bezisterim. Future operations are dependent on the success of ongoing development and commercialization efforts, as well as the ability to secure additional financing through sales of equity, loans, or other strategic transactions.

Management Comments

• "Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements."
• "Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions."
• "The Company believes that the claims [in the legal proceedings] are without merit and intends to defend vigorously against them, but there can be no assurances as to the outcome."

Industry Context

BioVie operates in the high-risk, high-reward biopharmaceutical sector, focusing on neurological and neurodegenerative disorders (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease. The company's drug candidate, bezisterim, targets inflammation-driven insulin resistance, an area of emerging scientific consensus for AD and PD. BIV201, for liver cirrhosis and ascites, leverages terlipressin, a drug already approved in the U.S. for related complications. The markets for these conditions are substantial, with millions of affected individuals, indicating significant unmet medical needs and potential market opportunities if successful. However, the industry is characterized by lengthy and expensive clinical trials, high failure rates, and intense regulatory scrutiny.

Legal Proceedings

• Consolidated securities class action lawsuit (In re BioVie Inc. Securities Litigation, No. 3:24-cv-00035) alleging material misrepresentations and/or omissions related to the NM101 Phase 3 study of bezisterim (NE3107) in mild to moderate probable AD, in violation of Sections 10(b) and 20(a) of the Exchange Act. The motion to dismiss was denied, and parties are now engaged in fact discovery.
• Consolidated shareholder derivative lawsuits (In re BioVie Inc. Derivative Litigation, Case No. 3:24-cv-0602-CSD) alleging breach of fiduciary duties, unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control, piggy-backing on the securities class action claims.

Related Party Transactions

• Acquisition of biopharmaceutical assets from NeurMedix, Inc., a privately held clinical-stage pharmaceutical company and a related party, in June 2021.
• Securities purchase agreement with Acuitas Group Holdings, LLC, the company's largest stockholder and former related party, on July 15, 2022, which included PIPE Shares and PIPE Warrants.
• Royalty obligations to LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc. (5.0% on net sales of BIV201) pursuant to the Agreement and Plan of Merger.
• Royalty obligations to the University of Padova (Italy) (low single digit royalty, capped at $200,000 per year) on net sales of terlipressin products covered by US patent no. 9,655,645.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity offerings and warrant exercises, significant uncertainty from ongoing legal proceedings, and the risk of value erosion due to the 'going concern' warning and AD trial issues. Conversely, successful clinical development could lead to substantial value creation.
• **Employees**: Benefit from continued employment and the 401K plan, but face uncertainty related to the company's financial viability and ongoing legal challenges.
• **Customers (future patients)**: Stand to benefit from the potential development of new drug therapies for neurological, neurodegenerative, and advanced liver diseases, particularly for conditions like Alzheimer's, Parkinson's, Long COVID, and ascites.
• **Creditors**: Exposed to increased risk due to the company's pre-revenue stage and the 'going concern' uncertainty, which may impact the ability to satisfy liabilities in the normal course of business.
• **Regulatory Authorities (FDA, DOD)**: Continued engagement and oversight for clinical trials and grant compliance, particularly in light of the reported cGCP violations in the AD trial.

Next Steps

• Engage in fact discovery for the consolidated securities class action and derivative lawsuits.
• Continue collecting and analyzing additional DNA methylation data for the Alzheimer's Disease trial.
• Finalize the protocol design for the Phase 3 study of BIV201 for liver cirrhosis and ascites.
• Consider employing the adaptive trial feature of the AD protocol to continue enrolling patients or designing a new Phase 3 study for bezisterim in AD.
• Secure additional financing to fund continuing operations and ongoing development programs.

Key Dates

Recommendation

The company faces severe challenges that warrant a 'sell' recommendation. The increased net loss and explicit 'going concern' warning signal fundamental financial instability. The integrity issues and protocol violations in the Alzheimer's Phase 3 trial, leading to patient exclusions and an underpowered study, represent a major setback for a key drug candidate and raise serious questions about data reliability and future regulatory pathways. The ongoing securities class action and derivative lawsuits add significant legal and reputational risk. While a recent capital raise provides temporary liquidity, it does not resolve the underlying operational and clinical hurdles. Given the pre-revenue stage, high burn rate, and significant uncertainties, the risk-reward profile is highly unfavorable for investors.

Keywords

BioVie Inc., BIVI, 10-Q, Quarterly Report, Clinical-stage, Neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disease, Long COVID, Liver disease, Ascites, Bezisterim, NE3107, BIV201, Terlipressin, Clinical trials, FDA, DOD grant, Public offering, Capital raise, Net loss, Going concern, Shareholder lawsuits, cGCP violations, Dilution